(Q52208050)

27 April 2018

title

Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma. (English)

1 reference

27 April 2018

1 reference

Falcone A

1

1 reference

27 April 2018

Antonuzzo A

2

1 reference

27 April 2018

Danesi R

3

1 reference

27 April 2018

Allegrini G

4

1 reference

27 April 2018

Monica L

5

1 reference

27 April 2018

Pfanner E

6

1 reference

27 April 2018

Masi G

7

1 reference

27 April 2018

Ricci S

8

1 reference

27 April 2018

Del Tacca M

9

1 reference

27 April 2018

Conte P

10

1 reference

27 April 2018

language of work or name

English

0 references

publication date

1 August 1999

1 reference

27 April 2018

published in

Cancer

1 reference

27 April 2018

volume

86

1 reference

27 April 2018

issue

3

1 reference

27 April 2018

page(s)

470-476

1 reference

27 April 2018

Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane.

cites work

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C470%3A%3AAID-CNCR15%3E3.0.CO%3B2-7

Effects of suramin on in vitro growth of fresh human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C470%3A%3AAID-CNCR15%3E3.0.CO%3B2-7

Suramin: an anticancer drug with a unique mechanism of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C470%3A%3AAID-CNCR15%3E3.0.CO%3B2-7

Suramin, an active drug for prostate cancer: interim observations in a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C470%3A%3AAID-CNCR15%3E3.0.CO%3B2-7

Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C470%3A%3AAID-CNCR15%3E3.0.CO%3B2-7

Phase II study of epirubicin in advanced hormone-resistant prostatic carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C470%3A%3AAID-CNCR15%3E3.0.CO%3B2-7

High dose epirubicin is effective in measurable metastatic prostate cancer: a phase II study of the EORTC Genitourinary Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C470%3A%3AAID-CNCR15%3E3.0.CO%3B2-7

Synergistic activity of suramin with tumor necrosis factor alpha and doxorubicin on human prostate cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C470%3A%3AAID-CNCR15%3E3.0.CO%3B2-7

Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C470%3A%3AAID-CNCR15%3E3.0.CO%3B2-7

Reporting results of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C470%3A%3AAID-CNCR15%3E3.0.CO%3B2-7

Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C470%3A%3AAID-CNCR15%3E3.0.CO%3B2-7

Development and validation of a pharmacokinetically based fixed dosing scheme for suramin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C470%3A%3AAID-CNCR15%3E3.0.CO%3B2-7

Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C470%3A%3AAID-CNCR15%3E3.0.CO%3B2-7

Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C470%3A%3AAID-CNCR15%3E3.0.CO%3B2-7

Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C470%3A%3AAID-CNCR15%3E3.0.CO%3B2-7

Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C470%3A%3AAID-CNCR15%3E3.0.CO%3B2-7

Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C470%3A%3AAID-CNCR15%3E3.0.CO%3B2-7

Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C470%3A%3AAID-CNCR15%3E3.0.CO%3B2-7

Suramin and prostate cancer: where do we go from here?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C470%3A%3AAID-CNCR15%3E3.0.CO%3B2-7

The use of adriamycin and its derivatives in the treatment of prostatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C470%3A%3AAID-CNCR15%3E3.0.CO%3B2-7

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C470%3A%3AAID-CNCR15%3E3.0.CO%3B2-7

Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C470%3A%3AAID-CNCR15%3E3.0.CO%3B2-7

Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C470%3A%3AAID-CNCR15%3E3.0.CO%3B2-7

Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819990801%2986%3A3%3C470%3A%3AAID-CNCR15%3E3.0.CO%3B2-7

10.1002/(SICI)1097-0142(19990801)86:3<470::AID-CNCR15>3.0.CO;2-7

21 January 2018

Identifiers

DOI

1 reference

27 April 2018

PubMed ID

10430255

1 reference

27 April 2018